Retatrutide 20MG (GLP-3 "RET")
Retatrutide is a synthetic investigational peptide designed as a triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. For Retatrutide, each vial is labeled 20MG, molecular formula C221H342N46O68, molecular weight approx. 4,731 Da, CAS 2381089-83-2.
Published laboratory work with Retatrutide has examined triple incretin receptor pharmacology, metabolic signaling pathway, glucose homeostasis investigations. Each lot is manufactured under sterile conditions, lyophilized in single-use research vials, and labeled with its production lot for traceability.
Supplied for in-vitro laboratory research use only. Not for human or veterinary consumption, administration, diagnostic or therapeutic use.
20MG research vial of retatrutide-class tri-agonist peptide for extended investigational studies.
Background reading on this compound in the ENOS Lab Notes: Retatrutide Phase 3 Update: Triple-Agonist Class Advances and The GLP Peptide Family Explained.
Background reading: Peptide Purity Testing and How to Read a Certificate of Analysis, HPLC vs Mass Spectrometry: What Each Test Actually Proves and Reconstitution and Storage Handling for Lyophilized Research Peptides.
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.
Compound identity
Listed on the storefront as GLP-3 "RET". The verified compound identity for this research vial is below.
- Compound name
- Retatrutide
- Also known as
- Retatrutide, LY3437943, GLP-3 RET, Triple agonist peptide
- Molecular formula
- C221H342N46O68
- Molecular weight
- Approximately 4,731 Da
- CAS number
- 2381089-83-2
- Vial size
- 20MG
Product Information
Research DatasheetProduct Overview
Retatrutide is a synthetic investigational peptide designed as a triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is widely studied in laboratory settings to investigate metabolic signaling, energy homeostasis, glucose regulation, lipid metabolism, and receptor pharmacology. This lyophilized research peptide is manufactured under sterile conditions. For laboratory research use only. Not for human or veterinary use.
Molecular Profile
Research Applications
- ◆Triple incretin receptor pharmacology
- ◆Metabolic signaling pathway research
- ◆Glucose homeostasis investigations
- ◆Energy expenditure studies
- ◆Lipid metabolism research
- ◆Endocrine signaling investigations
- ◆Receptor binding and activation studies
- ◆Obesity and metabolic disease laboratory models
- ◆Peptide pharmacokinetics and stability research
- ◆Drug discovery and translational peptide research
Quality Standards
For in-vitro research use only. Not for human consumption, diagnosis, or treatment.
20MG research vial of retatrutide-class tri-agonist peptide for extended investigational studies. All ENOS research vials are lyophilized, sealed under sterile conditions, and shipped with cold-chain packaging where appropriate.
You may also like
GLP-3 "RET"
GLP-3 "RET" · 10MG
Next-gen tri-agonist studied for metabolic modulation.
GLP-3 "RET"
GLP-3 "RET" · 60MG
Highest-yield retatrutide research vial.
GLP-2 "TIRZ"
GLP-2 "TIRZ" · 10MG
Dual GIP/GLP-1 agonist research peptide.